MedTrace Logo

Targeting Beta Cell Dysfunction With Verapamil in Longstanding T1D

NCT05847413 · Status: COMPLETED · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2023-05-06

No results posted yet for this study

Summary

The purpose of this study is to determine whether verapamil can transiently improve beta cell function in those who do or do not secrete proinsulin and little/no C-peptide.

Conditions

Interventions

DRUG

Verapamil

Subjects will receive oral verapamil for 12 weeks

Sponsors & Collaborators

  • Benaroya Research Institute

    lead OTHER

Principal Investigators

  • Carla Greenbaum, MD · Benaroya Research Institute

Study Design

Allocation
NA
Purpose
BASIC_SCIENCE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-05-30
Primary Completion
2021-12-10
Completion
2021-12-10
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05847413 on ClinicalTrials.gov